Management of Suspected Invasive Shigella with Negative Stool Culture
If clinical features strongly suggest invasive Shigella infection (bacillary dysentery with fever, bloody diarrhea, abdominal cramps, and tenesmus), treat empirically with antibiotics despite negative stool culture, as the clinical syndrome itself warrants treatment. 1
Clinical Decision Framework
The 2017 IDSA guidelines explicitly support empiric treatment for "ill immunocompetent people with fever documented in a medical setting, abdominal pain, bloody diarrhea, and bacillary dysentery (frequent scant bloody stools, fever, abdominal cramps, tenesmus) presumptively due to Shigella" even without microbiologic confirmation 1. This recommendation carries strong evidence quality.
Key Clinical Indicators That Support Treatment Without Culture Confirmation:
- Bacillary dysentery syndrome: Frequent, scant bloody stools with tenesmus
- Fever documented in medical setting
- Abdominal cramps and pain
- Recent international travel with temperature ≥38.5°C or signs of sepsis 1
Why Negative Cultures Don't Rule Out Shigella:
The sensitivity of dysentery (bloody stool) for identifying Shigella has declined over time, ranging from only 1.9-85.9% between 1977-2016 2. Critically, Shigella infection is associated with mortality (pooled OR 2.8), whereas dysentery presentation alone is not 2. This means many Shigella infections present without classic bloody diarrhea, and relying solely on culture or dysentery symptoms misses opportunities to reduce mortality.
Stool microscopy showing >50 WBC/hpf with any RBCs has only 67% sensitivity and 59% specificity for shigellosis 3, further supporting that negative initial testing doesn't exclude disease.
Empiric Antibiotic Selection
For Adults:
Choose either azithromycin OR a fluoroquinolone (ciprofloxacin), based on:
- Local resistance patterns
- Travel history
- Recent antimicrobial resistance data showing 52.9% azithromycin resistance, 64.7% TMP-SMX resistance, and 44.1% ciprofloxacin resistance in some regions 4
Given rising multidrug resistance (26.5% resistant to all three classes), azithromycin 1000mg single dose is increasingly preferred for empiric treatment 5, 4.
For Children:
- Infants <3 months: Third-generation cephalosporin
- Older children: Azithromycin based on local susceptibility patterns 1
Critical Caveats:
Rule out STEC first: If Shiga toxin-producing E. coli (especially O157:H7 or Stx2-producing strains) is suspected, avoid antibiotics entirely as they increase risk of hemolytic uremic syndrome 1. Look for low-grade or absent fever in acute dysentery as a clue to STEC rather than Shigella.
Immunocompromised patients: Have lower threshold for empiric treatment with severe illness and bloody diarrhea 1.
Reassess if no response: If symptoms persist beyond initial treatment course, consider non-infectious etiologies (IBD, IBS) after 14+ days, and reassess fluid/electrolyte balance and antimicrobial choice 1.
Emerging resistance: Recent data shows emergence of cephalosporin resistance and multidrug-resistant strains, particularly S. sonnei 4. Culture and susceptibility testing remain valuable when obtainable, even if treatment is initiated empirically.
Do Not Treat:
- Asymptomatic contacts 1
- Mild watery diarrhea without fever or dysentery syndrome in immunocompetent patients
- Cases where STEC cannot be excluded
The clinical syndrome of bacillary dysentery is sufficient justification for treatment, as Shigella-associated mortality is significant (OR 2.8) and current guidelines may miss mortality reduction opportunities by waiting for culture confirmation 2.